** Hong Kong shares of BeiGene Ltd 6160.HK jump 8.2% to HK$174.8, their highest since December 2021, and on course for fourth consecutive session of gains
** Stock on track for the biggest one-day rise since February 21
** Shanghai-listed stock 688235.SS surges 9.7% to record high at 248 yuan
** U.S. stock ONC.O jumped 7.5% on Thursday
** Chinese oncology treatments developer said its total global revenues increased 78% y/y to $1.1 bln for Q4 and it was up 55% y/y to $3.8 bln for the full year of 2024
** Full year 2025 revenue guidance of $4.9 bln to $5.3 bln - Co
** Nomura, with "Buy" rating on the stock, says 4Q24 sales beat on balanced growth in the U.S., China, EU with higher FY25E sales guided
** Hang Seng Commerce & Industry Index .HSNC and healthcare index .HSCIH both fall 1.8%, Hang Seng Index .HSI eases 1.7%
** Hong Kong-listed stock up 53.4% YTD, Shanghai shares up 50.6%, US shares up 50.7%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.